News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Patent Application Published for Prous Institute's SGLT2 Inhibitors (WO 2013045495)

Prous Institute for Biomedical Research is pleased to announce the publication of its new WIPO patent application: Pyrano[3,2-c][2]benzopyran-6(2H)-one derivatives and uses thereof.  Claimed  compounds have shown inhibitory activity against SGLT2 (type 2 sodium-glucose linked transporter) and have displayed positive effects in glycemia control in animal models. SGLT2 inhibitors promote the excretion of glucose in the urine and thereby reduce the accumulation of glucose in the body, making them an attractive model for the treatment of type 2 diabetes.

These novel molecules also have moderate platelet antiaggregatory activity, which can represent an added benefit since type 2 diabetes is characterized as a proinflammatory and procoagulant condition.

The new compounds have been developed through the application of Prous Institute's proprietary drug discovery platform SYMMETRY®.   The new molecular entities are the result of a search for new scaffolds for SLGT2 inhibition from natural products screening using SYMMETRY®’s powerful mechanism of action models.   In addition to SYMMETRY®’s  mechanism of action screening technologies (used to predict both on-target and off-target activities), Prous Institute has developed models to predict therapeutic activity, toxicity and adverse effects, and pharmacokinetics parameters, supporting decisions in the design and optimization of drug candidates.